Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SLC6A2 | P23975 | 7/20 | 0.49 |
| ▸ | SLC6A4 | P31645 | 7/20 | 0.49 |
| ▸ | SLC6A3 | Q01959 | 7/20 | 0.49 |
| ▸ | HTT | P42858 | 1/20 | 0.44 |
| ▸ | MAPK9 | P45984 | 2/20 | 0.43 |
| ▸ | SCN9A | Q15858 | 1/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4825300 | 1.00 | SLC6A2 (0.49) | SLC6A2SLC6A4SLC6A3HTTMAPK9 | |
| SCHEMBL4826093 | 1.00 | SLC6A2 (0.49) | SLC6A2SLC6A4SLC6A3HTTMAPK9 | |
| SCHEMBL4825312 | 1.00 | SLC6A2 (0.49) | SLC6A2SLC6A4SLC6A3HTTMAPK9 | |
| SCHEMBL4825304 | 1.00 | SLC6A2 (0.49) | SLC6A2SLC6A4SLC6A3HTTMAPK9 | |
| SCHEMBL4829839 | 0.89 | SLC6A4 (0.64) | SLC6A2SLC6A4SLC6A3HTT | |
| SCHEMBL4829834 | 0.89 | SLC6A4 (0.64) | SLC6A2SLC6A4SLC6A3HTT | |
| SCHEMBL4823170 | 0.89 | SLC6A4 (0.64) | SLC6A2SLC6A4SLC6A3HTT | |
| SCHEMBL4823183 | 0.89 | SLC6A4 (0.64) | SLC6A2SLC6A4SLC6A3HTT | |
| SCHEMBL4823178 | 0.89 | SLC6A4 (0.64) | SLC6A2SLC6A4SLC6A3HTT | |
| SCHEMBL4822978 | 0.85 | SLC6A2 (0.60) | SLC6A2SLC6A4SLC6A3HTTMAPK9 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20080119547-A1 | Aminoindane Derivatives As Serotonin And Norepinephrine Uptake Inhibitors | H. LUNDBECK A/S (DK) | 2008-05-22 | — | — | US | claimed |
| US-7351734-B2 | Aminoindane derivatives as serotonin and norepinephrine uptake inhibitors | H. LUNDBECK A/S (DK) | 2008-04-01 | — | — | US | claimed |
| US-20050085530-A1 | Aminoindane derivatives as serotonin and norepinephrine uptake inhibitors | H. LUNDBECK A/S (DK) | 2005-04-21 | — | — | US | claimed |
| EP-1458704-A1 | AMINOINDANE DERIVATIVES AS SEROTONIN AND NOREPINEPHRINE UPTAKE INHIBITORS | H. Lundbeck A/S (DK) | 2004-09-22 | — | — | EP | claimed |
| WO-2003055873-A1 | AMINOINDANE DERIVATIVES AS SEROTONIN AND NOREPINEPHRINE UPTAKE INHIBITORS | H. LUNDBECK A/S (DK) | 2003-07-10 | — | — | WO | claimed |
| US-20080119547-A1 | Aminoindane Derivatives As Serotonin And Norepinephrine Uptake Inhibitors | H. LUNDBECK A/S (DK) | 2008-05-22 | — | — | US | disclosed |
| US-7351734-B2 | Aminoindane derivatives as serotonin and norepinephrine uptake inhibitors | H. LUNDBECK A/S (DK) | 2008-04-01 | — | — | US | disclosed |
| US-20050085530-A1 | Aminoindane derivatives as serotonin and norepinephrine uptake inhibitors | H. LUNDBECK A/S (DK) | 2005-04-21 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080119547-A1 | Aminoindane Derivatives As Serotonin And Norepinephrine Uptake Inhibitors | SLC6A2, SLC18A2, SLC6A4 | SLC6A2 1/4885SLC6A4 3/4885SLC6A3 4/4885 |
| US-20050085530-A1 | Aminoindane derivatives as serotonin and norepinephrine uptake inhibitors | SLC6A2, SLC18A2, SLC6A4 | SLC6A2 1/4885SLC6A4 3/4885SLC6A3 4/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.